Use of Ozempic and Mounjaro, known as 'GLP-1 drugs,' has surged in recent years, with prescriptions increasing by more than 400% from 2019 to 2023, according to a report by the health policy organization KFF
Importantly, physical performance outcomes such as mobility and functional capacity are generally maintained, indicating that moderate lean mass loss during therapy does not necessarily equate to clinically relevant impairment [19, 26]
Ongoing clinical support, follow-ups, and monitoring are included as part of your program, so youre not navigating the process alone
Clinical Update 6/13/2023 Melatonin for Pelvic Pain
Neuroprotective Effects of Berberine in Animal Models of Alzheimer's Disease: a Systematic Review of Pre-clinical Studies